Aclaris Therapeutics (ACRS) Enterprise Value (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Enterprise Value of -$105.4 million for Q1 2026, little changed year-over-year from -$105.5 million in Q1 2025, and down 16.16% quarter-over-quarter from -$90.8 million in Q4 2025.
Aclaris Therapeutics (ACRS) Enterprise Value (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Enterprise Value history runs 13 years deep, the most recent figure standing at -$105.4 million for Q1 2026.
- In Q1 2026, Enterprise Value changed 0.1% year-over-year to -$105.4 million; the TTM figure through Mar 2026 stood at -$105.4 million (changed 0.1% YoY), while the FY2025 annual figure was -$90.8 million, up 20.11% from the prior year.
- Enterprise Value for Q1 2026 stood at -$105.4 million, down from -$90.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$90.8 million in Q4 2025, with the low at -$248.6 million in Q2 2022.
- The 5-year median for Enterprise Value is -$119.1 million (2023), against an average of -$140.3 million.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value sank 40.01% in 2022, then jumped 58.46% in 2023.
- Aclaris Therapeutics' Enterprise Value stood at -$217.6 million in 2022, then jumped by 45.26% to -$119.1 million in 2023, then climbed by 4.63% to -$113.6 million in 2024, then grew by 20.11% to -$90.8 million in 2025, then retreated by 16.16% to -$105.4 million in 2026.
- Business Quant data shows ACRS's Enterprise Value at -$105.4 million in Q1 2026, -$90.8 million in Q4 2025, and -$95.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | -91.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -91.56 Mn |
| Mar 31, 2026 | -105.42 Mn |
| Dec 31, 2025 | -90.75 Mn |
| Sep 30, 2025 | -95.91 Mn |
| Jun 30, 2025 | -99.81 Mn |
| Mar 31, 2025 | -105.31 Mn |
| Dec 31, 2024 | -113.59 Mn |
| Sep 30, 2024 | -127.72 Mn |
| Jun 30, 2024 | -111.09 Mn |
| Mar 31, 2024 | -128.17 Mn |
| Dec 31, 2023 | -119.11 Mn |
| Sep 30, 2023 | -103.05 Mn |
| Jun 30, 2023 | -119.78 Mn |
| Mar 31, 2023 | -170.80 Mn |
| Dec 31, 2022 | -217.57 Mn |
| Sep 30, 2022 | -248.06 Mn |
| Jun 30, 2022 | -248.60 Mn |
| Mar 31, 2022 | -179.62 Mn |
| Dec 31, 2021 | -191.41 Mn |
| Sep 30, 2021 | -197.88 Mn |